A new $4 million grant will support the establishment of a health economics research facility to evaluate and compare the economic value of available interventions in the criminal-legal system. The researchers aim to develop tools and resources for policymakers to identify strategic investments in substance use disorder care.
Researchers are building an AI-powered database of MRI and CT images to track disease progression and measure patient response to treatments. The database will provide a standardized toolkit for extracting precise imaging biomarkers, enhancing the accuracy of organ measurements and improving treatment choices.
Dr. Lauren Henderson, a pediatric rheumatologist, has been awarded the 10th annual Gale and Ira Drukier Prize in Children’s Health Research. Her research focuses on children with difficult-to-treat juvenile idiopathic arthritis and other autoimmune disorders, exploring how the immune system goes awry in these conditions.
Researchers at Weill Cornell Medicine develop a new method to generate functional endothelial cells from adult tissue, potentially enabling vascular grafts and organ transplants. The approach involves using small molecules to trigger cell division without aging or losing function.
A new multi-omics tool, GoT-Multi, has enabled researchers to gain insights into how cancers evolve towards greater aggressiveness and therapy resistance. The tool can analyze diverse types of pathology samples and quickly process large numbers of cells, revealing new details about cancer progression.
Researchers discovered that an enzyme called EZH2 drives triple negative breast cancer cells to divide abnormally, enabling them to spread. Inhibiting EZH2 with drugs like tazemetostat restored order to dividing cells and thwarted the spread of TNBC cells.
The AR² Center will replicate, validate and reproduce existing autism research results using various data sets. The center aims to foster public trust in the field by providing transparent communication of scientific findings.
Researchers developed a molecular tool called SCOPE that can capture proteins binding to DNA, enabling identification of protein regulators. The tool was used to discover new protein regulators of human stem cell-related genes, revealing the roles of two proteins in maintaining stem cells and one in inducing differentiation.
A successful HIV vaccine could be a major public health breakthrough, preventing 1.3 million new infections in 2024 and saving lives from the virus. The new childhood vaccine is based on the Env trimer protein complex and aims to elicit broadly neutralizing antibodies in young immune systems.
Dr. Carl Nathan's groundbreaking research has advanced our understanding of innate immunity, tuberculosis, and cancer. His discovery of macrophage-activating factor (MAF) and its role in driving immune responses has led to the development of new treatments for previously intractable diseases.
A four-year NIH grant will support a study of type 1 diabetes, led by Dr. Shuibing Chen at Weill Cornell Medicine. The researchers will investigate the interplay between genetic and environmental triggers using advanced laboratory and computational tools.
A new preclinical study from Weill Cornell Medicine suggests that inflammation during pregnancy may prime offspring for anxiety. The researchers discovered that adversity in the womb configured a small percentage of brain cells to be overly active when faced with a threatening situation, creating a vulnerability to anxiety.
Ana Campos Codo, a Weill Cornell Immunology and Microbial Pathogenesis Ph.D. student, has been selected for the 2025 cohort of the HHMI Gilliam Fellows Program. The program provides $65,000/year support for up to three years to students and their faculty thesis advisors.
A new study published in JAMA Network Open found that older adults living in flood-hit areas in New Jersey faced a 5% higher risk of heart disease for up to five years after Hurricane Sandy's landfall. Flooded ZIP code areas had lower median incomes and higher area deprivation index scores, which are linked to worse health outcomes.
A scientific team co-led by Dr. Lishomwa Ndhlovu at Weill Cornell Medicine has received an NIH MERIT Award to study a handful of people who have managed to clear HIV after a stem cell transplant. The goal is to identify the immune mechanisms that led to remission and develop a broadly applicable immunotherapy for eliminating HIV.
Dr. Greenblatt's discovery of distinct types of bone-building stem cells has opened new areas of research into targeted therapies for bone cancer, osteoporosis, and rare bone conditions. His work has identified potential therapeutic targets to block spine metastases in breast and prostate cancer.
Researchers have developed a stable Env protein trimer, SOSIP.664, that can elicit broadly neutralizing antibodies against HIV. The breakthrough came after decades of work and multiple modifications to the protein, which is harder to engineer than its counterpart on SARS-CoV-2.
Weill Cornell Medicine leads a $14.9M NIH grant program to remove latent HIV from cells, aiming for effective cures. Researchers will use a personalized approach to develop tailored immunotherapies and broadly neutralizing antibodies against HIV.
Neurons in the gut produce adrenomedullin 2, which expands group 2 innate lymphoid cells and provides therapeutic benefit in inflammatory bowel disease preclinical models. Elevated expression of ADM2 was found in patients with inflammatory bowel disease, suggesting a promising therapeutic target.
Weill Cornell Medicine researchers Dr. Anna Nam and Dr. Maria Cecilia Lira have been awarded prestigious Pew fellowships to support their innovative cancer and biomedical science research. Dr. Nam is investigating the genetic determinants of Hodgkin lymphoma, while Dr. Lira aims to develop novel therapies for brain tumors.
NewYork-Presbyterian/Weill Cornell Medical Center has been recognized as a mitral valve repair reference center by the Mitral Foundation for three consecutive years. The award highlights the institution's commitment to delivering high-quality care and advancing best practices in surgical treatment of mitral valve disease.
A new clinical research study found that young children lacked immunity to common respiratory viruses during the pandemic, leading to a post-pandemic resurgence. The study's findings enable more accurate predictions for future outbreaks and demonstrate the utility of longitudinal immunologic surveillance in children.
A new analysis suggests that young people with weaker connections between brain areas involved in anxiety are more likely to benefit from a self-guided anxiety care app. The study found that the app reduced anxiety symptoms for many patients, particularly those with weaker neural connections.
A new study found that one in six men with low-grade prostate cancer (GG1) actually have intermediate- or high-risk cancer when other clinical features are considered. This suggests that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment.
Weill Cornell Medicine researchers found that PD-1 plays a critical role in forming long-term immune defenders in the skin. Blocking PD-1 too early can disrupt this process, leading to side effects. The study challenges current understanding of PD-1 and may impact cancer treatments.
A $1.1 million grant supports a natural history study for MCHS, collecting vital information about the condition to inform future clinical trials of therapies. The Volāre Study aims to provide baseline developmental trajectory information and establish infrastructure for multicenter clinical trials.
Researchers discovered that PAR1 triggers a structural transformation in lymphatic vessels, making them more permeable to absorb excess fluid and immune cells. This finding has implications for the treatment of lung diseases and could lead to targeted therapies.
A new study from Weill Cornell Medicine sheds light on age-related liver changes that may lead to chronic diseases. The research reveals that aging disrupts the functional organization of liver cells, causing inflammation and impaired metabolism.
A new combination treatment strategy selectively targets ovarian tumor cells, reducing growth in preclinical models. The approach identifies effective regimens to treat genetically diverse cancers by blocking specific growth signaling pathways.
A recent study published in Nature Metabolism found that electrical activity in synapses can lead to the use of lipid droplets as an energy source in the brain. Researchers discovered that neurons can break down fat into fatty acids and produce ATP, even when glucose is not present.
Academic medical centers can transform patient care by adopting learning health system principles, harnessing real-time data analysis and AI to improve patient outcomes. The proposed model aims to establish a smarter, more efficient and equitable care model by integrating diverse databases and leveraging AI for personalized, proactive ...
A new preclinical study from Weill Cornell Medicine found that a combination of small molecules extended the survival of transplanted pancreatic islets in female mice, while adding two molecules to the mixture boosted cell survival in male mice. This breakthrough could allow physicians to treat more patients with fewer cells.
Researchers have discovered that a rare genetic mutation delays Alzheimer's disease by suppressing inflammatory signaling in the brain. The study found that inhibiting this pathway with a drug-like inhibitor replicated key protective effects of the mutation in a preclinical model.
A new study published in JAMA found that youth who become increasingly addicted to social media, mobile phones, or video games are at greater risk of suicidal thoughts and behaviors. The research suggests that limiting screen time may not be effective in reducing the risk of mental health problems.
The INSIGHT Clinical Research Network has received $13.5 million in funding to expand its patient data network, increasing capacity for observational studies and retrospective studies. The network will support research on conditions including depression, diabetes, breast cancer, heart disease, and Alzheimer’s disease.
Dr. Warren Johnson receives the Weill Award for his transformative work in global health, including research and training programs in Brazil, Haiti, and Tanzania. He has mentored over 70 physicians and physician-scientists, including Dr. Daniel Fitzgerald.
Using an algorithm called the Krakencoder, researchers at Weill Cornell Medicine mapped how the brain's anatomical connections and activity patterns relate to behavior. The tool accurately predicted individual's functional connectome about 20 times more than previous approaches, also mapping age, sex, and cognitive performance scores.
Dr. Ghosh's expertise combines clinical, social science, and policy research to address the impact of climate change on vulnerable populations. His initiatives focus on developing interventions against heatwaves, hurricanes, and flooding.
Dr. Nikolaos Koundouros has been awarded the 2025 Tri-Institutional Breakout Award for his research on how cells detect and respond to dietary nutrients, specifically omega-6 and omega-3 fatty acids, in relation to breast cancer development.
A new study found that tumors with multiple sites undergo significant genetic changes, including whole-genome duplication, when they metastasize. This led researchers to wonder why copy-number alterations are more common than mutations in metastatic tumors.
A large clinical trial found that switching to an experimental drug after liquid biopsy detection of treatment-resistant mutations in breast cancer patients substantially extends tumor control and overall health status. The study, conducted at Weill Cornell Medicine, showed better outcomes compared to standard care.
Weill Cornell Medicine researchers Dr. Juan R. Cubillos-Ruiz and Dr. David Lyden have been awarded a $750,000 grant to study ovarian cancer, with a focus on harnessing immune cells and detecting the disease earlier. Their research aims to develop innovative strategies for eliminating metastatic tumors and preventing recurrence.
Researchers at Weill Cornell Medicine have made new discoveries about BCG therapy, which has been shown to reprogram and amplify immune cells in the bone marrow, boosting the body's ability to fight cancer. The findings could lead to improved immunotherapies for various types of cancer.
Four Weill Cornell Medicine investigators received the Ritu Banga Healthcare Disparities Research Awards to tackle disparities in cancer care, racial and ethnic differences in pediatric Hodgkin lymphoma, and access barriers to high-quality surgical cancer care. The awards support innovative research aimed at improving health outcomes f...
A team of researchers at Weill Cornell Medicine has discovered that the malaria parasite Plasmodium falciparum can shut down a key set of genes to avoid detection by the immune system. This finding suggests that asymptomatic adults may harbor undetectable parasites, making it more challenging to eliminate malaria.
A new study has identified three social risk clusters associated with a higher risk of suicide in the US, highlighting the importance of broader community-level social conditions. The findings suggest that region-specific interventions addressing poverty, housing, and environmental stressors can help lower suicide rates.
A 72-week clinical trial found tirzepatide to be more effective than semaglutide in reducing body weight and waist circumference. The study demonstrated that tirzepatide's dual mechanism of action, mimicking both GLP-1 and GIP hormones, is key to its superior performance.
A new AI-based method accurately sorts cancer patients into groups with similar characteristics before treatment and similar outcomes after treatment. The approach showed better performance than standard statistical and machine learning methods in predicting treatment outcomes from health record data.
A new $4 million grant will test whether Prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) Computed Tomography (CT) can improve prostate cancer monitoring while reducing screening-related harms. The study aims to reduce the need for biopsies in men with low- or intermediate-risk prostate cancers.
Researchers found that a chemical modification on messenger RNAs triggers disposal while being read by the ribosome, but during cell stress, this process is halted, allowing stress-response proteins to accumulate and help cells recover. The study may have implications for cancer therapies targeting m6A modifications.